Pyrotinib and trastuzumab combination treatment synergistically overcomes HER2 dependency in HER2-positive breast cancer: insights from the PHILA trial
This work was supported by the National Key Research and Development Program of China (2021YFF1201300), the National Natural Science Foundation of China (82172875), the CAMS Innovation Fund for Medical Sciences (CIFMS) (2022-I2M-2-001), and the Joint Innovative Fund of Beijing Natural Science Foundation and Changping District (L234004).
Authors
- Lixi Li (ORCID: https://orcid.org/0000-0001-5790-5052)
- Binghe Xu (ORCID: https://orcid.org/0000-0003-4195-337X)
- Fei Ma (ORCID: https://orcid.org/0000-0001-9432-1902)
- Yuanyi Wang (ORCID: https://orcid.org/0000-0002-6163-5144)
- Haili Qian (ORCID: https://orcid.org/0000-0003-0652-4801)
- Bo Lan (ORCID: https://orcid.org/0000-0002-2962-439X)
- Cheng Zeng (ORCID: https://orcid.org/0000-0002-9350-0244)
- Shuning Liu (ORCID: https://orcid.org/0000-0003-4473-8237)
- Tao Yang (ORCID: https://orcid.org/0000-0002-3348-4377)
- Hewei Ge (ORCID: https://orcid.org/0000-0002-9852-2733)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- National Cancer Center (US)
Publication Details
- Journal
- EBioMedicine
- Published
- 2024-10-04
- DOI
- https://doi.org/10.1016/j.ebiom.2024.105379
- Citations
- 16
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 4.52
Funders
- National Natural Science Foundation of China
- National Key Research and Development Program of China